Review
Urology & Nephrology
Panagiotis I. Georgianos, Rajiv Agarwal
Summary: The article discusses the detrimental effects of MR overactivation in CKD models on the heart, kidney, and blood vessels, as well as the potential of Finerenone as a novel MR antagonist to improve the progression of cardiorenal disease.
KIDNEY INTERNATIONAL REPORTS
(2021)
Article
Peripheral Vascular Disease
Ryo Nakamaru, Koichi Yamamoto, Hiroshi Akasaka, Hiromi Rakugi, Isao Kurihara, Takashi Yoneda, Takamasa Ichijo, Takuyuki Katabami, Mika Tsuiki, Norio Wada, Tetsuya Yamada, Hiroki Kobayashi, Kouichi Tamura, Yoshihiro Ogawa, Junji Kawashima, Nobuya Inagaki, Megumi Fujita, Kenji Oki, Kohei Kamemura, Akiyo Tanabe, Mitsuhide Naruse
Summary: The study found that female patients with bilateral primary aldosteronism have worse renal outcomes compared to male patients after receiving mineralocorticoid receptor antagonist treatment. Despite similar systolic blood pressure levels between the sexes, women experienced a greater decline in estimated glomerular filtration rate, especially during the late phase of 6 to 60 months post-treatment initiation.
Article
Urology & Nephrology
Michele Provenzano, Maria Jesus Puchades, Carlo Garofalo, Niels Jongs, Luis D'Marco, Michele Andreucci, Luca De Nicola, Jose Luis Gorriz, Hiddo J. L. Heerspink
Summary: This study assessed the efficacy and safety of SGLT2 inhibitors and mineralocorticoid receptor antagonists in patients with CKD. The results showed that changes in urinary albumin did not correlate between dapagliflozin and eplerenone, but the combination of these drugs resulted in a strong additive effect in lowering UACR.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Review
Peripheral Vascular Disease
Atsuhisa Sato, Mitsuhiro Nishimoto
Summary: This article summarizes the latest evidence on the use of nonsteroidal MR antagonists in the treatment of diabetic kidney disease (DKD). It highlights the effectiveness of MR antagonists and suggests measures for managing hyperkalemia. The study emphasizes the importance of continuous use of MR antagonists in DKD treatment.
HYPERTENSION RESEARCH
(2022)
Article
Peripheral Vascular Disease
Daigoro Hirohama, Mitsuhiro Nishimoto, Nobuhiro Ayuzawa, Wakako Kawarazaki, Wataru Fujii, Shigeyoshi Oba, Shigeru Shibata, Takeshi Marumo, Toshiro Fujita
Summary: The study revealed that the activation of the Rac1-MR pathway contributes to the progression of DKD by causing hypertension and podocyte injury, highlighting MR antagonism and Rac1 inhibition as a novel strategy for DKD treatment.
Review
Pharmacology & Pharmacy
Daiji Kawanami, Yuichi Takashi, Yoshimi Muta, Naoki Oda, Dai Nagata, Hiroyuki Takahashi, Makito Tanabe
Summary: Diabetic kidney disease is a major cause of end-stage kidney disease worldwide, with the mineralocorticoid receptor playing an important role in its development. Clinical studies have shown the benefits of MR antagonists for DKD, but concerns remain about their selectivity and hyperkalemia risks. New nonsteroidal MRAs, such as finerenone, have been developed with high selectivity and potent anti-inflammatory and anti-fibrotic properties, and a lower risk of hyperkalemia.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Pharmacology & Pharmacy
Ulrich Kintscher, George L. Bakris, Peter Kolkhof
Summary: This review provides information on the molecular pharmacology and relevant clinical data of a new class of non-steroidal MRAs, discussing their cardiorenal outcomes. These compounds have an improved benefit-risk profile in treating cardiovascular diseases, and finerenone has a novel indication.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Peripheral Vascular Disease
George Bakris, Pablo E. Pergola, Belkis Delgado, Diyan Genov, Tamar Doliashvili, Nam Vo, Y. Fred Yang, James McCabe, Vincent Benn, Bertram Pitt
Summary: In patients with resistant or poorly controlled hypertension and advanced chronic kidney disease, the nonsteroidal mineralocorticoid receptor antagonist KBP-5074 effectively lowers blood pressure with some risk of hyperkalemia.
Review
Behavioral Sciences
Claire L. Pince, Kimberly E. Whiting, Tammy Wang, Andras H. Leko, Lisa A. Farinelli, Diane Cooper, Mehdi Farokhnia, Leandro F. Vendruscolo, Lorenzo Leggio
Summary: This scoping review summarizes the role of aldosterone and mineralocorticoid receptor (MR) in addiction and the potential effects of pharmacological manipulations of MR on addiction-related outcomes. The findings suggest that dysregulations of aldosterone and MR occur in both peripheral and central systems and are influenced by drug exposure patterns and genetic factors. Antagonism of MR holds promise as a potential target for the treatment of addiction, but further research is needed.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS
(2023)
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Luis M. Ruilope, Peter Rossing, George L. Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage, Bertram Pitt
Summary: Finerenone reduces the incidence of new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, regardless of a history of HF.
Review
Medicine, General & Internal
Gates B. Colbert, Mohamed E. Elrggal, Anna Gaddy, Hector M. Madariaga, Edgar V. Lerma
Summary: Hypertension is a key factor in the progression of cardiovascular disease in patients with chronic kidney disease, particularly diabetic kidney disease. Controlling hypertension can delay the progression of diabetic kidney disease. Several medications have been proven effective in real-world use, and new drugs are emerging.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, Dimitrios Farmakis, Luis M. Ruilope, Peter Rossing, Johann Bauersachs, Robert J. Mentz, Peter Kolkhof, Charlie Scott, Amer Joseph, George L. Bakris, Stefan D. Anker
Summary: In the FIDELIO-DKD trial, finerenone improved cardiorenal outcomes in patients with CKD and T2D regardless of history of heart failure.
EUROPEAN JOURNAL OF HEART FAILURE
(2022)
Review
Chemistry, Medicinal
Nina Vodosek Hojs, Sebastjan Bevc, Robert Ekart, Nejc Piko, Tadej Petreski, Radovan Hojs
Summary: Diabetes and chronic kidney disease are global health issues with a strong connection, as diabetic kidney disease affects a significant portion of diabetic patients. Non-steroidal mineralocorticoid receptor antagonists (MRA) have shown promise in treating DKD with fewer side effects compared to steroidal MRAs. Research in this area continues to expand to optimize treatment options.
Review
Pharmacology & Pharmacy
Zachary M. Howard, Chetan K. Gomatam, Arden B. Piepho, Jill A. Rafael-Fortney
Summary: Duchenne muscular dystrophy (DMD) is a muscle degenerative disease caused by the loss of dystrophin protein. Current standard-of-care treatment for DMD has limited efficacy and serious side effects. Mineralocorticoid receptor antagonists (MRAs) have shown promise as a therapeutic target for DMD, as they can improve muscle function and reduce inflammation and fibrosis.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Tom T. G. F. Lieverse, Maria J. Puchades, Udo D. J. Mulder, Michele Provenzano, Guido Krenning, Niels Jongs, Simon E. Wink, Riemer H. J. A. Slart, Michele Andreucci, Luis D'Marco, Luca De Nicola, Jose L. Gorriz, Hiddo J. L. Heerspink
Summary: This study aimed to investigate the effects of sodium-glucose co-transporter 2 inhibitors and mineralocorticoid receptor antagonists on markers of the glomerular endothelial glycocalyx and tubular function. The results showed that dapagliflozin and eplerenone had different effects on these markers, indicating different mechanistic pathways for their kidney protective effects.
DIABETES OBESITY & METABOLISM
(2023)
Article
Oncology
Arif Ul Hasan, Wararat Kittikulsuth, Fuminori Yamaguchi, Tuba Musarrat Ansary, Asadur Rahman, Yuki Shibayama, Daisuke Nakano, Hirofumi Hitomi, Masaaki Tokuda, Akira Nishiyama
EXPERIMENTAL CELL RESEARCH
(2017)
Review
Biochemistry & Molecular Biology
Asadur Rahman, Arif Ul Hasan, Akira Nishiyama, Hiroyuki Kobori
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2018)
Article
Multidisciplinary Sciences
Asadur Rahman, Daisuke Yamazaki, Abu Sufiun, Kento Kitada, Hirofumi Hitomi, Daisuke Nakano, Akira Nishiyama
Article
Multidisciplinary Sciences
Tuba M. Ansary, Yoshihide Fujisawa, Asadur Rahman, Daisuke Nakano, Hirofumi Hitomi, Hideki Kobara, Tsutomu Masaki, Jens M. Titze, Kento Kitada, Akira Nishiyama
SCIENTIFIC REPORTS
(2017)
Review
Biochemistry & Molecular Biology
Arif Ul Hasan, Asadur Rahman, Hiroyuki Kobori
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2019)
Article
Biochemistry & Molecular Biology
Abu Sufiun, Asadur Rahman, Kazi Rafiq, Yoshihide Fujisawa, Daisuke Nakano, Hideki Kobara, Tsutomu Masaki, Akira Nishiyama
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Oncology
Asadur Rahman, Makoto Matsuyama, Akio Ebihara, Yuki Shibayama, Arif Ul Hasan, Hironori Nakagami, Fumiaki Suzuki, Jiao Sun, Tomoe Kobayashi, Hiroki Hayashi, Daisuke Nakano, Hideki Kobara, Tsutomu Masaki, Akira Nishiyama
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Biology
Yuki Shibayama, Kazuo Takahashi, Hisateru Yamaguchi, Jun Yasuda, Daisuke Yamazaki, Asadur Rahman, Takayuki Fujimori, Yoshihide Fujisawa, Shinji Takai, Toru Furukawa, Tsutomu Nakagawa, Hiroyuki Ohsaki, Hideki Kobara, Jing Hao Wong, Tsutomu Masaki, Yukio Yuzawa, Hideyasu Kiyomoto, Shinichi Yachida, Akihiro Fujimoto, Akira Nishiyama
COMMUNICATIONS BIOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Asadur Rahman, Tatsuya Sawano, Anupoma Sen, Akram Hossain, Nourin Jahan, Hideki Kobara, Tsutomu Masaki, Shinji Kosaka, Kento Kitada, Daisuke Nakano, Takeshi Imamura, Hiroyuki Ohsaki, Akira Nishiyama
Summary: Esaxerenone, a nonsteroidal and selective mineralocorticoid receptor blocker, improved survival and cardiac function, reduced blood pressure and cardiac remodeling in Dahl salt-sensitive rats fed a high-salt diet, indicating its potential in mitigating cardiac dysfunction in salt-induced myocardial injury.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Environmental Sciences
Sumaya Akter, Akhi Moni, Golam Mahbub Faisal, Muhammad Ramiz Uddin, Nourin Jahan, Md Abdul Hannan, Asadur Rahman, Md Jamal Uddin
Summary: Both acute and chronic kidney diseases are significant health issues worldwide. Synthetic therapeutics developed so far have unexpected effects, leading researchers to explore natural alternatives. Mangiferin, a natural compound from mango, has shown renoprotective potential against kidney diseases. Studies have demonstrated that mangiferin can attenuate renal inflammation and oxidative stress, improve renal function, and ameliorate structural changes in the kidney. However, further research is needed to understand the targeted delivery of mangiferin to the kidney for clinical use.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Biochemistry & Molecular Biology
Mai Hattori, Asadur Rahman, Satoshi Kidoguchi, Nourin Jahan, Yoshihide Fujisawa, Norihiko Morisawa, Hiroyuki Ohsaki, Hideki Kobara, Tsutomu Masaki, Akram Hossain, Akumwami Steeve, Akira Nishiyama
Summary: This study investigated the effects of the nonsteroidal mineralocorticoid receptor blocker esaxerenone on blood pressure and renal health in salt-loaded conditions. The results showed that esaxerenone significantly reduced blood pressure and attenuated renal damage induced by high salt intake. These effects were associated with the modulation of sodium homeostasis by esaxerenone.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Asadur Rahman, Nourin Jahan, Md Tanvir Rahman, Akira Nishiyama
Summary: Inappropriate mineralocorticoid receptor (MR) activation in cardiovascular cells has negative effects on cardiac remodeling and function. MR inhibition is an important strategy to overcome cardiovascular dysfunction, but the clinical application of steroidal MR antagonists is limited due to adverse effects. Newer non-steroidal MR antagonists show promise for clinical use, particularly in patients with type 2 diabetes and chronic kidney disease. Pre-clinical and clinical evidence supports the use of non-steroidal MR antagonists in treating cardiovascular disease.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Gastroenterology & Hepatology
Hirohito Mori, Asadur Rahman, Tsutomu Masaki
DIGESTIVE ENDOSCOPY
(2017)
Letter
Pharmacology & Pharmacy
Asadur Rahman, Yoshihide Fujisawa, Daisuke Nakano, Hirofumi Hitomi, Akira Nishiyama
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
(2017)
Article
Gastroenterology & Hepatology
Hirohito Mori, Asadur Rahman, Hideki Kobara, Shintaro Fujihara, Noriko Nishiyama, Maki Ayaki, Tae Matsunaga, Masanori Murakami, Tsumomu Masaki